AtriCure, Inc.ATRC

AtriCure, Inc. reported second-quarter 2026 revenue of $153.6 million, a 12.8% year-over-year increase, yet the company’s net income for the quarter was a paltry $108,000. The $644 million asset base and $146.2 million in cash suggest strength, but operating cash flow was negative $4 million, and inventories ballooned by $2.8 million to $81.1 million. The company’s own product pages highlight surgical ablation therapies and devices like the AtriClip and CryoICE BOX, yet the ledger tells a quieter story of stockpiling and R&D spend that outstrips profit. (source: Press Release dated July 23, 2026, relating to financial results for the second quarter ended June 30, 2026, https://www.sec.gov/Archives/edgar/data/1323885/000132388526000032/exhibit991-7232026.htm)

AtriCure designs and sells surgical treatments and therapies for atrial fibrillation, the left atrial appendage, and post-operative pain management. Its product portfolio includes the AtriClip device for left atrial appendage management and the CryoICE BOX, a cryoablation system released in stages from 2023 to 2025. The company’s clinical evidence page points to trials like the Post-Approval Study of the AtriCure Bipolar Radiofrequency Ablation of Permanent Atrial Fibrillation, which aims to demonstrate the safety and effectiveness of the Cox Maze IV procedure using the AtriCure Bipolar System. (source: AtriCure, Inc., Official product/news rail, https://www.atricure.com/healthcare-professionals/product-labeling)

The company’s 10-Q for the quarter ending March 31, 2026, shows revenue of $141.2 million, net income of $108,000, operating income of $526,000, and a net loss from operating activities of $4 million. Assets totalled $644 million, liabilities $152.3 million, and stockholders’ equity $491.7 million. Cash and equivalents stood at $146.2 million, with inventories at $81.1 million and an increase of $2.8 million during the period. Research and development expenses were $24.2 million, while capital expenditures were $3.9 million. Diluted EPS was $0.00, based on 49 million weighted average shares outstanding. (source: SEC EDGAR 10-Q filing, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1323885/000132388526000030/atrc-20260723_10q.htm)

For a deeper look at the company’s product pipeline and clinical evidence, the official product pages and clinical trials results provide a window into AtriCure’s pipeline of ablation therapies and devices. However, the gap between the company’s revenue growth and its net income remains a stubborn feature of the ledger. (source: AtriCure, Inc., Official product/news rail, https://www.atricure.com/healthcare-professionals/clinical-evidence/trials-results; AtriCure, Inc., Official product/news rail, https://www.atricure.com/patients-caregivers/clinical-evidence/trials-results)

The SEC EDGAR filings for AtriCure, Inc. provide the raw ledger behind the polished product story. The 8-K filed on July 23, 2026, and the 10-Q for the quarter ending March 31, 2026, are the primary sources for the financial figures cited here. The product pages and clinical evidence pages round out the picture but do not alter the fundamental tension between revenue growth and profitability. (source: SEC EDGAR filing index for AtriCure, Inc., https://www.sec.gov/edgar/browse/?CIK=1323885; SEC EDGAR companyfacts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0001323885.json)

What remains unproven is whether AtriCure can convert its revenue momentum and product pipeline into sustained profitability. The company’s cash position is strong, but the operating cash flow deficit and inventory build-up suggest working capital pressures. The next earnings release and 10-Q will be critical in determining whether the gap between growth and profit is narrowing or widening. (source: Press Release dated July 23, 2026, relating to financial results for the second quarter ended June 30, 2026, https://www.sec.gov/Archives/edgar/data/1323885/000132388526000032/exhibit991-7232026.htm; SEC EDGAR 10-Q filing, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1323885/000132388526000030/atrc-20260723_10q.htm)